Correspondence 0001213900-23-044985 from Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp.
Date: June 1, 2023 · CIK: 0001841330 · Accession: 0001213900-23-044985
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271896
Letter
Re:
June 1, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Pasithea Therapeutics Corp. (the “Company”)
Registration Statement on Form S-3 (File No. 333-271896)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on June 5, 2023, or as soon as practicable thereafter.
Please call James O’Grady of Lowenstein Sandler LLP at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
PASITHEA THERAPEUTICS CORP.
Show Raw Text
CORRESP
1
filename1.htm
June 1, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Pasithea Therapeutics Corp. (the “Company”)
Registration Statement on Form S-3 (File No. 333-271896)
Ladies and Gentlemen:
In accordance with Rule 461 under
the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on June 5, 2023, or as soon
as practicable thereafter.
Please call James O’Grady
of Lowenstein Sandler LLP at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
PASITHEA THERAPEUTICS CORP.
By:
/s/ Tiago Reis Marques
Name:
Tiago Reis Marques
Title:
Chief Executive Officer
(Principal Executive Officer)